Isoray Inc (ISR) 2.42 $ISR
Market Momentum on Biotech Stocks -- IsoRay, Neurocrine Biosciences, OPKO Health, Orexigen Therapeutics, and Gilead Sciences
PR Newswire - Thu Jul 31, 7:40AM CDT
On Wednesday, July 30, 2014, the NASDAQ Composite ended at 4,462.90, up 0.45%, the Dow Jones Industrial Average finished the day 0.19% lower at 16,880.36, and the S&P 500 closed at 1,970.07, up 0.01%. During the session five out of ten sectors ended in positive. The S&P 500 Health Care Sector Index ended the day at 718.94, up 0.36%, and the index has advanced 2.05% in the last one month. Investor-Edge has initiated coverage on the following equities: IsoRay Inc. (NYSE MKT: ISR), Neurocrine Biosciences Inc. (NASDAQ: NBIX), OPKO Health Inc. (NYSE: OPK), Orexigen Therapeutics Inc. (NASDAQ: OREX), and Gilead Sciences Inc. (NASDAQ: GILD). Free research on these five companies can be accessed at:
Why IsoRay (ISR) Stock Is Spiking Today
at The Street - Mon Jul 14, 10:41AM CDT
IsoRay (ISR) shares are climbing after the company's Cesium-131 internal radiation seeds were used in the world's first successful stereotactic brain implant surgery.
Hot Stock: IsoRay, Shares Gain 7.7% (ISR)
Comtex SmarTrend(R) - Mon Jul 14, 10:39AM CDT
IsoRay (AMEX:ISR) is one of today's best performing low-priced stocks, up 7.7% to $2.95 on 1.1x average daily volume. Thus far today, IsoRay has traded 2.9 million shares, vs. average volume of 2.7 million shares per day. The stock has outperformed the Dow (7.7% to the Dow's 0.8%) and outperformed the S&P 500 (7.7% to the S&P's 0.6%) during today's trading.
IsoRay Makes First Cesium-131 Delivery for Treatment of an Inoperable Brain Cancer Afflicting a Young Child in Peru
Marketwire - Mon Jul 14, 7:30AM CDT
IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced the first Cesium-131 seed shipment to Peru for the treatment of a Glioma brain tumor located near the brainstem.
IsoRay Announces Its Addition to the Russell Microcap Index
Marketwire - Mon Jun 30, 7:45AM CDT
IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for cancers of the brain, lung, head and neck, prostate and gynecologic ("gyn"
, today announced that it has been added to the Russell Microcap Index.
A Beaten-Down Biotech Stock Gearing Up for a Big Squeeze Higher
at The Street - Tue Jun 24, 1:22PM CDT
The shorts are betting against this biotech stock, but its technical chart is telling a different story.
Traders Get Bullish on Shares of IsoRay, Shares Up 15.2% (ISR)
Comtex SmarTrend(R) - Tue Jun 24, 10:09AM CDT
IsoRay (AMEX:ISR) is one of today's best performing low-priced stocks, up 15.2% to $3.08 on 5.1x average daily volume. IsoRay has traded 9.9 million shares thus far today, vs. average volume of 1.9 million shares per day. The stock has outperformed the Dow (15.2% to the Dow's 0.1%) and outperformed the S&P 500 (15.2% to the S&P's 0.3%) during today's trading.
Why IsoRay (ISR) Stock Is Surging Today
at The Street - Tue Jun 24, 9:38AM CDT
IsoRay (ISR) surged Tuesday after the company announced the world's first liquid cesium-131 treatment for metastatic brain cancer.
IsoRay Announces World's First Liquid Cesium-131 (Cesitrex(R)) Treatment for Metastatic Brain Cancer Utilizing the GliaSite(R) Radiation Therapy Balloon Catheter System
Marketwire - Tue Jun 24, 7:45AM CDT
IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced another milestone -- the treatment of a brain tumor that had metastasized from esophageal cancer utilizing IsoRay's liquid Cesium-131 (Cesitrex(R)) which recently was FDA cleared for internal radiation therapy.
Health Care Sector Stocks Technical Analysis -- Research on United Therapeutics, IsoRay, Bruker, and Affymetrix
PR Newswire - Mon Jun 23, 6:50AM CDT
On Friday, June 20, 2014, the NASDAQ Composite ended at 4,368.04, up 0.20%, the Dow Jones Industrial Average finished the session at 16,947.08, up 0.15% and the S&P 500 closed at 1,962.87, up 0.17%. During the trading session, five out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day 0.84% higher at 702.66, and the index has advanced 3.99% in the previous three months. Investor-Edge has initiated coverage on the following equities: United Therapeutics Corp. (NASDAQ: UTHR), IsoRay Inc. (NYSE MKT: ISR), Bruker Corp. (NASDAQ: BRKR) and Affymetrix Inc. (NASDAQ: AFFX). Free technical research on UTHR, ISR, BRKR and AFFX can be downloaded upon signing up at:
IsoRay Announces New Russian and Peruvian International Distributor Agreements for the Sale of IsoRay's Full Line of Products
Marketwire - Fri Jun 20, 7:45AM CDT
IsoRay, Inc. (NYSE MKT: ISR) (http://www.isoray.com/), announced today that it has entered into two (2) international distribution agreements: the first with MedikorPharma-Ural LLC for the Russian market and the other with Surgicorp SRL for the Peruvian market. IsoRay is a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for brain cancer, lung cancer, head and neck cancer, prostate cancer and gynecologic ("gyn" cancer.
5 Stocks Under $10 Set to Soar
at The Street - Thu Jun 05, 12:58PM CDT
These under-$10 stocks look ready to break out and trade higher from current levels.
Three biotechs stocks with positive institutional transactions, good price to cash ratios and "buy" recommendations from street analysts
ACCESSWIRE - Thu May 22, 7:09AM CDT
LOS ANGELES / ACCESSWIRE / May 22, 2014 / The names of big-board biotechnology listed firms IsoRay, Inc. (NYSE MKT: ISR), CEL-SCI Corporation (NYSE MKT: CVM), and Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), came up after we set out to find low price biotech stocks with market caps in the $50m to $300m range which, based on a fixed set of fundamental and technical criteria, might be hinting at bullish investment trade sentiments.
Hot Stock: IsoRay, Shares Gain 22.3% (ISR)
Comtex SmarTrend(R) - Tue Apr 01, 10:10AM CDT
IsoRay (AMEX:ISR) is one of today's best performing low-priced stocks, up 22.3% to $2.69 on 1.4x average daily volume. IsoRay has traded 16.0 million shares thus far today, vs. average volume of 11.1 million shares per day. The stock has outperformed the Dow (22.3% to the Dow's 0.4%) and outperformed the S&P 500 (22.3% to the S&P's 0.4%) during today's trading.
IsoRay (ISR) Rallies Ahead of Major Conference
at The Street - Tue Apr 01, 9:55AM CDT
IsoRay (ISR) is rallying on Tuesday ahead of its participation in a major medical conference toward the end of the week.
IsoRay Announces Five Presentations at the American Brachytherapy Society (ABS) Convention Reporting on the Ongoing Success of Cesium-131 in Fighting Cancer
Marketwire - Tue Apr 01, 7:46AM CDT
IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it will host a booth (#301) at the Annual Meeting of the American Brachytherapy Society (ABS). The annual ABS meeting will take place April 3-5, 2014 in San Diego, California at the Manchester Grand Hyatt.
Market Momentum on Biotech Stocks -- IsoRay, Neurocrine Biosciences, OPKO Health, Orexigen Therapeutics, and Gilead Sciences
PR Newswire - Thu Jul 31, 7:40AM CDT
On Wednesday, July 30, 2014, the NASDAQ Composite ended at 4,462.90, up 0.45%, the Dow Jones Industrial Average finished the day 0.19% lower at 16,880.36, and the S&P 500 closed at 1,970.07, up 0.01%. During the session five out of ten sectors ended in positive. The S&P 500 Health Care Sector Index ended the day at 718.94, up 0.36%, and the index has advanced 2.05% in the last one month. Investor-Edge has initiated coverage on the following equities: IsoRay Inc. (NYSE MKT: ISR), Neurocrine Biosciences Inc. (NASDAQ: NBIX), OPKO Health Inc. (NYSE: OPK), Orexigen Therapeutics Inc. (NASDAQ: OREX), and Gilead Sciences Inc. (NASDAQ: GILD). Free research on these five companies can be accessed at:
Why IsoRay (ISR) Stock Is Spiking Today
at The Street - Mon Jul 14, 10:41AM CDT
IsoRay (ISR) shares are climbing after the company's Cesium-131 internal radiation seeds were used in the world's first successful stereotactic brain implant surgery.
Hot Stock: IsoRay, Shares Gain 7.7% (ISR)
Comtex SmarTrend(R) - Mon Jul 14, 10:39AM CDT
IsoRay (AMEX:ISR) is one of today's best performing low-priced stocks, up 7.7% to $2.95 on 1.1x average daily volume. Thus far today, IsoRay has traded 2.9 million shares, vs. average volume of 2.7 million shares per day. The stock has outperformed the Dow (7.7% to the Dow's 0.8%) and outperformed the S&P 500 (7.7% to the S&P's 0.6%) during today's trading.
IsoRay Makes First Cesium-131 Delivery for Treatment of an Inoperable Brain Cancer Afflicting a Young Child in Peru
Marketwire - Mon Jul 14, 7:30AM CDT
IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced the first Cesium-131 seed shipment to Peru for the treatment of a Glioma brain tumor located near the brainstem.
IsoRay Announces Its Addition to the Russell Microcap Index
Marketwire - Mon Jun 30, 7:45AM CDT
IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for cancers of the brain, lung, head and neck, prostate and gynecologic ("gyn"
, today announced that it has been added to the Russell Microcap Index. A Beaten-Down Biotech Stock Gearing Up for a Big Squeeze Higher
at The Street - Tue Jun 24, 1:22PM CDT
The shorts are betting against this biotech stock, but its technical chart is telling a different story.
Traders Get Bullish on Shares of IsoRay, Shares Up 15.2% (ISR)
Comtex SmarTrend(R) - Tue Jun 24, 10:09AM CDT
IsoRay (AMEX:ISR) is one of today's best performing low-priced stocks, up 15.2% to $3.08 on 5.1x average daily volume. IsoRay has traded 9.9 million shares thus far today, vs. average volume of 1.9 million shares per day. The stock has outperformed the Dow (15.2% to the Dow's 0.1%) and outperformed the S&P 500 (15.2% to the S&P's 0.3%) during today's trading.
Why IsoRay (ISR) Stock Is Surging Today
at The Street - Tue Jun 24, 9:38AM CDT
IsoRay (ISR) surged Tuesday after the company announced the world's first liquid cesium-131 treatment for metastatic brain cancer.
IsoRay Announces World's First Liquid Cesium-131 (Cesitrex(R)) Treatment for Metastatic Brain Cancer Utilizing the GliaSite(R) Radiation Therapy Balloon Catheter System
Marketwire - Tue Jun 24, 7:45AM CDT
IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced another milestone -- the treatment of a brain tumor that had metastasized from esophageal cancer utilizing IsoRay's liquid Cesium-131 (Cesitrex(R)) which recently was FDA cleared for internal radiation therapy.
Health Care Sector Stocks Technical Analysis -- Research on United Therapeutics, IsoRay, Bruker, and Affymetrix
PR Newswire - Mon Jun 23, 6:50AM CDT
On Friday, June 20, 2014, the NASDAQ Composite ended at 4,368.04, up 0.20%, the Dow Jones Industrial Average finished the session at 16,947.08, up 0.15% and the S&P 500 closed at 1,962.87, up 0.17%. During the trading session, five out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day 0.84% higher at 702.66, and the index has advanced 3.99% in the previous three months. Investor-Edge has initiated coverage on the following equities: United Therapeutics Corp. (NASDAQ: UTHR), IsoRay Inc. (NYSE MKT: ISR), Bruker Corp. (NASDAQ: BRKR) and Affymetrix Inc. (NASDAQ: AFFX). Free technical research on UTHR, ISR, BRKR and AFFX can be downloaded upon signing up at:
IsoRay Announces New Russian and Peruvian International Distributor Agreements for the Sale of IsoRay's Full Line of Products
Marketwire - Fri Jun 20, 7:45AM CDT
IsoRay, Inc. (NYSE MKT: ISR) (http://www.isoray.com/), announced today that it has entered into two (2) international distribution agreements: the first with MedikorPharma-Ural LLC for the Russian market and the other with Surgicorp SRL for the Peruvian market. IsoRay is a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for brain cancer, lung cancer, head and neck cancer, prostate cancer and gynecologic ("gyn"
cancer. 5 Stocks Under $10 Set to Soar
at The Street - Thu Jun 05, 12:58PM CDT
These under-$10 stocks look ready to break out and trade higher from current levels.
Three biotechs stocks with positive institutional transactions, good price to cash ratios and "buy" recommendations from street analysts
ACCESSWIRE - Thu May 22, 7:09AM CDT
LOS ANGELES / ACCESSWIRE / May 22, 2014 / The names of big-board biotechnology listed firms IsoRay, Inc. (NYSE MKT: ISR), CEL-SCI Corporation (NYSE MKT: CVM), and Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), came up after we set out to find low price biotech stocks with market caps in the $50m to $300m range which, based on a fixed set of fundamental and technical criteria, might be hinting at bullish investment trade sentiments.
Hot Stock: IsoRay, Shares Gain 22.3% (ISR)
Comtex SmarTrend(R) - Tue Apr 01, 10:10AM CDT
IsoRay (AMEX:ISR) is one of today's best performing low-priced stocks, up 22.3% to $2.69 on 1.4x average daily volume. IsoRay has traded 16.0 million shares thus far today, vs. average volume of 11.1 million shares per day. The stock has outperformed the Dow (22.3% to the Dow's 0.4%) and outperformed the S&P 500 (22.3% to the S&P's 0.4%) during today's trading.
IsoRay (ISR) Rallies Ahead of Major Conference
at The Street - Tue Apr 01, 9:55AM CDT
IsoRay (ISR) is rallying on Tuesday ahead of its participation in a major medical conference toward the end of the week.
IsoRay Announces Five Presentations at the American Brachytherapy Society (ABS) Convention Reporting on the Ongoing Success of Cesium-131 in Fighting Cancer
Marketwire - Tue Apr 01, 7:46AM CDT
IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it will host a booth (#301) at the Annual Meeting of the American Brachytherapy Society (ABS). The annual ABS meeting will take place April 3-5, 2014 in San Diego, California at the Manchester Grand Hyatt.
